Lineage Cell Therapeutics (LCTX) Free Cash Flow Growth (1y) (2011 - 2026)
Lineage Cell Therapeutics (LCTX) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 60.84% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 88.70% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.72% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 66.37% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn | -63.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63.52% |
| Dec 31, 2025 | 19.91% |
| Sep 30, 2025 | 40.46% |
| Jun 30, 2025 | -6.87% |
| Mar 31, 2025 | 14.40% |
| Dec 31, 2024 | -0.39% |
| Sep 30, 2024 | -28.86% |
| Jun 30, 2024 | 20.36% |
| Mar 31, 2024 | 49.07% |
| Dec 31, 2023 | 15.40% |
| Sep 30, 2023 | 20.20% |
| Jun 30, 2023 | 8.87% |
| Mar 31, 2023 | -152.29% |
| Dec 31, 2022 | -31.28% |
| Sep 30, 2022 | -17.63% |
| Jun 30, 2022 | -29.11% |
| Mar 31, 2022 | 393.99% |
| Dec 31, 2021 | -4.77% |
| Sep 30, 2021 | -2.32% |
| Jun 30, 2021 | -30.62% |